Testing
PanCED® Pan-Cancer Early Detection
- Comprehensive cancer risk assessment
- Early detection enables more effective and timely treatment
- Reduced treatment costs by avoiding late-stage care
- Peace of mind, especially for those with a family history of cancer
Age2U® Discover Your Biological and Organ-Specific Age
- Your biological age versus your chronological age
- The aging status of key organ systems (e.g. cardiovascular, metabolic, immune and nervous)
- How diet, sleep, stress, and environment influence your aging process
Why It Matters:
Knowing your biological age helps you take early, targeted steps to maintain vitality, prevent disease, and extend your healthy years.
Ideal For Individuals Who Want To:
- Evaluate the effectiveness of healthy aging or wellness programs
- Create a science-based personalized treatment planning
Alzheimer2U™ A Personalized Test For Alzheimer's
Disease Genotyping And Risk Monitoring
Identify your lifetime genetic risk before the onset of Alzheimer’s disease (AD).
AD is a name that sparks fear for many, a relentless neurodegenerative condition affecting tens of millions of families across the globe. As our population rapidly ages, the need for effective prevention and early intervention has never been more urgent. Against this backdrop, APOE genetic testing is emerging as a powerful new tool that helps reveal an individual’s genetic risk for AD.
APOE genetic testing provides us with a new window into understanding the genetic risk of AD. However, it is only a risk-assessment tool, not a diagnostic test. When facing AD, we should remain rational, take proactive preventive measures, and look forward together to future medical breakthroughs.
How It Works
The apolipoprotein E (APOE) gene encodes ApoE, a key protein essential for lipid transport and neuronal repair. Alzheimer2U analyzes the three major APOE alleles—ε2, ε3, and ε4—to estimate an individual’s lifetime genetic risk of developing AD.
Studies have shown that carrying one APOE ε4 allele increases the risk of developing the disease by 3–4 times, while carrying two ε4 alleles raises the risk by 10–15 times. In contrast, the APOE ε2 allele has a protective effect and can reduce disease risk. It is important to note that APOE ε4 is not a causative gene but a risk gene. This means that carrying ε4 does not necessarily lead to the disease; it only indicates a higher risk.
- Lifetime Risk Assessment: Estimates genetic predisposition to AD based on APOE allele patterns.
- Early Intervention: Supports earlier cognitive screening and adoption of lifestyle modifications to reduce modifiable risks.
- Precision Medicine: Guides the recommended frequency of follow-up, intensity of screening, and need for adjunct biomarker testing.
- Individuals with a strong family history of dementia or AD
- Adults aged 40 or above with early signs of cognitive decline or personal concern
- People in high-risk groups undergoing preventive health screening
- Individuals undergoing assessment before entering preventive or cognitive-wellness programs
GutSCI™ Helicobacter pylori and Gastrointestinal Health
Helicobacter pylori is a common bacterium that infects the stomach lining and is estimated to affect more than half of the world’s population. While many infected individuals may not experience symptoms, long-term H. pylori infection can lead to serious gastrointestinal diseases, including chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric (stomach) cancer. Due to its strong link to gastric cancer, the World Health Organization (WHO) has classified H. pylori as a Group I carcinogen, meaning there is clear evidence that it can cause cancer in humans.
Virulence of H. pylori: Type I and Type II Strains
Not all H. pylori infections carry the same risk. Certain strains, known as Type I (virulent) strains, possess specific virulence genes such as cagA and vacA, which are associated with increased inflammation, tissue damage, and a higher risk of gastric cancer and MALT lymphoma. In contrast, Type II (less virulent) strains lack some of these high-risk genes and are generally associated with milder disease. Identifying the virulence type helps clinicians better assess disease risk and guide patient management.
Current Methods to Detect H. pylori
Traditional diagnostic methods for H. pylori include both invasive and non-invasive approaches. Invasive methods, such as endoscopy with biopsy, allow direct examination of the stomach but are uncomfortable, costly, and not suitable for large-scale screening. Non-invasive tests, including urea breath tests, blood antibody tests, and stool antigen tests, are more patient-friendly but often provide limited information on bacterial virulence or antibiotic resistance.
Our Non-Invasive, PCR-Based Stool Test Solution
Our approach is fully non-invasive, using a simple fecal (stool) sample. By applying advanced PCR-based genotyping, we are able not only to detect the presence of H. pylori, but also to identify key virulence gene, helping to distinguish higher-risk infections from lower-risk ones. This provides clinically meaningful information without the need for endoscopy or hospital-based procedures.
Antibiotic Resistance in Malaysia
Antibiotic resistance in H. pylori is a growing concern in Malaysia, with increasing resistance reported for commonly used antibiotics such as clarithromycin, metronidazole, and levofloxacin. This resistance can lead to treatment failure and repeated infections. Using the same feces sample, our test can also detect genetic markers associated with antibiotic resistance, enabling more informed treatment decisions and supporting personalised therapy rather than trial-and-error prescribing.
Colorectal Cancer (CRC) in Malaysia: A Growing Health Burden
Colorectal cancer (CRC) is the second most common cancer in Malaysia, affecting both men and women, with a higher prevalence observed in males. Many CRC cases are diagnosed at later stages, when treatment options are more limited. Early detection is therefore critical to improving survival and outcomes.
Why Stool-Based CRC Testing Works
The gastrointestinal tract naturally sheds millions of cells into feces every day, including cells from pre-cancerous lesions and tumours. This makes stool an ideal, non-invasive sample for CRC screening. By analysing stool DNA, highly sensitive and specific molecular tests can detect cancer-related genetic or epigenetic changes, even at early stages of disease.
One Sample, Multiple Insights
By using a single fecal sample, our platform offers a comprehensive gastrointestinal health assessment—screening for H. pylori, identifying virulence and antibiotic resistance, and supporting early detection of colorectal cancer. This integrated, non-invasive approach improves patient comfort, increases screening uptake, and enables earlier, more personalised intervention for better long-term health outcomes.
- Have a personal history of stomach or colorectal cancer, or have previously been diagnosed with bowel polyps
- Are aged 50 years and above, when the risk of gastrointestinal cancers naturally increases
- Have a close family member (parent, sibling, or child) who has been diagnosed with colorectal cancer or bowel polyps
- Have inherited conditions that increase cancer risk, such as familial adenomatous polyposis (FAP) or Lynch syndrome
- Live with long-term bowel inflammation, including ulcerative colitis or Crohn’s disease
- Notice signs of gastrointestinal bleeding, such as black stools or visible blood in the stool
- Experience ongoing digestive symptoms, including persistent indigestion, abdominal pain or discomfort, a noticeable abdominal lump, or unexplained weight loss
OncoSCI® Molecular Profiling for Precision Oncology
No two cancers are the same — even within the same type.
OncoSCI® provides comprehensive molecular profiling of tumors to guide personalized treatment decisions.
Using Next-Generation Sequencing (NGS), it analyzes the genetic and molecular features of a tumor to reveal how it grows, spreads, and responds to therapy.
What OncoSCI® Provides:
- Identification of genetic mutations, biomarkers, and pathways driving cancer
- Insights to optimize targeted therapy, immunotherapy and chemotherapy
- Deeper understanding of tumor behavior and resistance mechanisms
- Oncologists and hospitals managing complex cancer cases
- Patients seeking personalized, evidence-based treatment strategies
Traditional cancer care often follows a one-size-fits-all approach. OncoSCI® empowers clinicians to deliver the right treatment to the right patient at the right time.
DPYD & UGT1A1 Genotyping for Safer Chemotherapy
Reducing Toxicity, Improving Outcomes
DPYD and UGT1A1 genotyping are pharmacogenomic tests that help identify patients at increased risk of severe or life‑threatening toxicity from commonly used chemotherapy agents. By understanding how an individual metabolizes specific drugs before treatment begins, clinicians can personalize therapy, improve safety, and optimize outcomes.
What Is DPYD Genotyping?
The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for breaking down fluoropyrimidine drugs, including 5‑Fluorouracil (5‑FU), Capecitabine and Tegafur.
Why DPYD Testing Matters?
Patients with reduced or absent DPD activity are unable to properly metabolize fluoropyrimidines. This can lead to excessive drug exposure and severe toxicity, including profound neutropenia, severe diarrhea and mucositis, neurotoxicity and potentially fatal adverse reactions.
DPYD genotyping identifies clinically relevant variants associated with reduced enzyme activity, allowing clinicians to adjust dosing or select alternative therapies before treatment begins.
What Is UGT1A1 Genotyping?
The UGT1A1 gene encodes the enzyme uridine diphosphate glucuronosyltransferase 1A1, which is critical for metabolizing irinotecan and bilirubin.
Why UGT1A1 Testing Matters?
Certain UGT1A1 variants (most notably UGT1A1*28) reduce enzyme activity, increasing the risk of irinotecan‑related toxicity, such as severe neutropenia, debilitating diarrhea and treatment interruptions or hospitalizations.
UGT1A1 genotyping helps guide irinotecan dosing decisions and supports safer use of this effective chemotherapy agent.
Who Should Consider Testing?
DPYD and/or UGT1A1 genotyping may be recommended for:
- Patients planned for fluoropyrimidine‑based chemotherapy
- Patients planned for irinotecan‑containing regimens
- Individuals with a personal or family history of severe chemotherapy toxicity
- Patients requiring higher‑dose or combination chemotherapy
Testing is typically performed before treatment initiation, but may also be useful after unexpected toxicity.
- Improved patient safety through early identification of high‑risk individuals
- Personalized dosing based on genetic risk
- Reduced treatment‑related toxicity and hospital admissions
- Greater confidence in treatment planning
Products
AGE Reader mu Non-Invasive Cardiovascular & Metabolic Health Testing
The AGE Reader mu is a quick, non-invasive diagnostic device that measures Advanced Glycation End Products (AGEs) — harmful compounds that accumulate in tissues with age.
High AGE levels are linked to cardiovascular disease, diabetes, and metabolic disorders. Measuring them provides valuable insight into your vascular health and metabolic resilience.
What AGE Reader mu Does:
- Measures AGEs in skin tissue using safe, light-based technology
- Provides instant results — no needles, no blood samples
- Evaluates cardiovascular and metabolic health risks
We collaborate across multiple sectors to bring molecular testing into routine care:
Science-Based. Preventive. Personalized.
At SCI Laboratories, we go beyond standard health screening and diagnostics — delivering deep molecular insights that reveal how your body is aging, how diseases may develop, and how you can take action before symptoms appear.
Our mission is simple:
To understand the science of biology, build resilience against aging, and live a healthier, and more vibrant life.
Integration Across Healthcare Sectors
- Clinics: Preventive and wellness screening for patients
- Hospitals: Molecular profiling and precision oncology support
- Wellness Centres: Integration of biological age testing into anti-aging programs
For individual clients, testing is conducted through our trusted medical partners.
If you’re interested in our tests, we’ll connect you with a certified hospital or clinic for consultation and sample collection.